



BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015.

Tel. : 0731-2723016 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com

Factory : Plot No. 8, Sector - III, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.) PIN - 454 775

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)

Tel. : 0731-2426700, 2426718 • CIN : L24233MP1985PLC002709

Date: 25th August, 2020

To,
The Company Secretary,
Corporate Compliance Department
The National Stock Exchange of India
Limited
Bandra Kurla Complex, Mumbai

To,
The Company Secretary
Corporate Compliance Department
BSE Limited
Dalal Street, P.J. Tower, Mumbai

Sub: Submission of Un-Audited Financial Result for the quarter ended on 30th June, 2020 and Limited Review Report thereon.

Scripe Code: 524396; Sripe Id: BIOFILCHEM, ISIN No INE829A01014

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, we are hereby enclosing Un-Audited Financial Results together with Limited Review Report thereon for the quarter 30th June 2020 duly approved by the Board of Directors of the Company at its meeting held today i.e. on Tuesday, 25th August, 2020.

Further, copy of Un-Audited Financial Statements shall also be submitted in XBRL mode (Excel Template provided by Exchange) within 24 hours from the conclusion of Board Meeting.

The aforesaid results will be published in one Hindi (vernacular) and widely circulated English Newspaper. The Results shall also be uploaded on website of Stock Exchanges i.e. www.bseindia.com and www.nseindia.com and on the website of the Company at www.biofilgroup.net.

You are requested to take on record the above said financial results for your reference and record.

Yours Faithfully

For Biofil Chemicals and Pharmaceuticals Limited

Ramesh Shah

Managing Director

(DIN No. 00028819)

Encl: a/a



Biofil Chemicals and Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN L24233MP1985PLC002709

Email Id: bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17 Website: www.biofilgroup.net

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2020

(Amount in Lakhs except EPS)

Statement of Unaudited Financial Results for the quarter ended 30th June 2020					
Sr No.	Particulars	3 Month Ended 30/06/2020	3 Month Ended 30/06/2019	3 Month Ended 31/03/2020	Year ended March 31 2020
		Unaudited	Unaudited	Audited	Audited
I	Revenue from Operation	230.11	159.41	371.52	2969.02
II	Other Income	63.62	1.11	3.81	17.15
III	Total Revenue (I + II)	293.72	160.52	375.34	2986.17
IV	Expenses				
	(a) Cost of materials consumed	139.65	86.67	137.64	405.66
	(b) Purchases of stock-in-trade	1209.89	25.03	3.28	2159.45
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1122.16)	(13.95)	88.05	-34.23
	(d) Employee benefits expense	16.75	18.97	13.41	86.34
	(e) Finance Cost	2.45	3.59	2.50	12.24
	(f) Depreciation and Amortisation Expense	10.21	9.13	12.80	40.83
	(g) Other expenses	15.27	27.19	77.19	169.47
	Total expenses (IV)	272.06	156.64	334.89	2839.76
V	Profit/ (Loss) before exceptional items and tax (III-IV)	21.66	3.89	40.45	146.41
VI	Exceptional Items	0.00	0.00	0.00	0.00
VII	Profit/ (Loss) before tax (V - VI)	21.66	3.89	40.45	146.41
VIII	Tax expense:				
	(1) Current tax	0.00	0.00	25.69	25.69
	(2) Deferred tax Credit/ (Charge)	0.00	0.00	0.00	0.00
IX	Profit/(Loss) for the period from continuing operation (VII-VIII)	21.66	3.89	14.76	120.72
X	Profit/(Loss) from dis-continued operation	0.00	0.00	0.00	0.00
XI	Tax expenses of discontinued operation	0.00	0.00	0.00	0.00
XII	Profit/(Loss) from dis-continued operation after tax (X-XI)	0.00	0.00	0.00	0.00
XIII	Profit/ (Loss) for the period (IX+XII)	21.66	3.89	14.76	120.72
XIV	Other Comprehensive Income	0.00	0.00	0.00	0.00
	A) (I) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00
	(II) Income Tax relating to items that will not be reclassified to Profit or Loss				
	B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00
	(II) Income Tax relating to items that will be reclassified to Profit or Loss				
	c) Other Comprehensive Income (net of tax)	0.00	0.00	2.62	2.62
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)	21.66	3.89	17.39	123.35
XVI	Paid-Up equity share capital (face value of Rs 10/- each)	1627.38	1627.38	1627.38	1627.38




XVII	Reserves (Excluding Revaluation Reserve)				
XVIII	Earnings per equity shares (for continuing operation):				(515.27)
	(1) Basic (Rs)	0.13	0.02	0.11	0.76
	(2) Diluted (Rs)	0.13	0.02	0.11	0.76

- 1 The above results for the Quarter ended June 30, 2020 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on 25-08-2020. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
- 2 This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 3 The figures of the previous period / year have been re-stated / re-grouped / re-arranged / reclassified and / or recasted wherever found necessary.
- 4 The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments
 - a. Pharma Product
 - b. Chemicals Division
- 5 The aforesaid un-audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors
- 6 The figures for the quarter ended March 31, 2020 are the balancing figures between the audited figures in respect of the full financial year and the years to date figures up to the third quarter which were subjected to limited review.

Date : 25-08-2020

Place : Indore

For Biofil Chemicals & Pharmaceuticals Limited



RAMESH SHAH
MANAGING DIRECTOR
(DIN: 00028819)

Biofil Chemicals and Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)
CIN L24233MP1985PLC002709

Email Id: bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17

Segmentwise Revenue, Results and Capital Employed for quarter ended 30th June-2020


S.No.	Segment Revenue	(Amount in Lakhs)			
		Quarter Ended		Year Ended	
		June 30 ,	March 31,	June 30 ,	March 31,
		2020	2020	2019	2020
		Reviewed	Audited	Reviewed	Audited
1	Segment Revenue				
	Pharma Unit	24.75	233.89	55.59	2,436.17
	Chemicals Division	205.35	137.63	103.82	532.85
	Plastic Division	0.00	0.00	0.00	0.00
	Other	63.62	9.05	1.11	19.77
	Gross Turnover	293.72	380.57	160.52	2,988.79
2	Segment Results				
	Pharma Unit	(9.92)	(6.94)	8.06	91.41
	Chemicals Division	34.01	48.30	2.96	67.60
	Plastic Division	0.00	(2.18)	(3.56)	(6.81)
	Other	0.00	0.00	0.00	0.00
	Total Segment Profit Before Tax	24.09	39.18	7.45	152.20
	Interest Income	0.00	(0.45)	0.00	2.16
	Interest Expenses	2.44	(4.34)	3.56	5.33
	Other Unallocable Income net of Expenditure				
	Profit Before Tax	21.66	43.07	3.89	149.03
	Provision for current tax	0.00	24.88	0.00	24.88
	Item Related Earlier Year	0.00	0.81	0.00	0.81
	Profit After Tax	21.66	17.39	3.89	123.35
3	Capital Employed				
	Segment Assets (A)				
	Pharma Division	2,125.11	3,017.03	1,340.63	3,017.03
	Chemicals Division	1,228.95	1,219.47	1,014.01	1,219.47
	Plastic Division	0.00	0.00	50.05	0.00
	Other				
	Total (A)	3,354.06	4,236.49	2,404.69	4,236.49
	Segment Liabilities (B)				
	Pharma Division	1,519.12	2,404.93	735.37	2,404.93
	Chemicals Division	254.79	343.24	180.20	343.24
	Plastic Division	0.00	0.00	150.79	0.00
	Other				
	Total (B)	1,773.91	2,748.18	1,066.35	2,748.18
	Total Capital Employed (Segment Assets-Segment Liabilities)				
	Pharma Division	605.99	612.09	605.27	612.09
	Chemicals Division	974.16	876.22	833.81	876.22
	Plastic Division	0.00	0.00	(100.74)	0.00
	Other				
	Total Capital Employed (Segment Assets-Segment Liabilities)	1,580.15	1,488.32	1,338.34	1,488.32

Plastic division operation has been discontinued from 14-02-2020 However Comparative figures have been incorporated in Segment results.

DATE : 25/08/2020

PLACE: INDORE

BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.



RAMESH SHAH
MANAGING DIRECTOR
DIN: 00028819



Review report to Biofil Chemicals and Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited financial results of **Biofil Chemicals and Pharmaceuticals Limited** for the period ended 30th June 2020 being submitted by the Company pursuant to Regulation 33 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including relevant circular issued by the SEBI from time to time.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Indian Accounting Standard 34, Interim Financial Reporting (Ind As 34) prescribed under section 133 of Companies Act 2013 and generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

Place: Indore
Date: 25.08.2020

For Maheshwari & Gupta
Chartered Accountants

FRN: 006179C

CA Sunil Maheshwari
Partner

M No.403346

UDIN: 20403346AAAAFN1801